Skip to main content
SpringerLink
Log in

Erkrankungen des lymphatischen Systems

  • Chapter
Medizinische Therapie 2005|2006

  • 34 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur

  • Behringer K, Josting A, Schiller P et al. (2004) Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. Ann Oncol 15(7): 1079–1085

    Article  CAS  PubMed  Google Scholar 

  • Canellos et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 327:1478

    CAS  PubMed  Google Scholar 

  • Carde P, Noordijk EM, Hagenbeek A et al. (1997) Superiority of EBVP chemotherapy in combination with involved field irradiation (EBVP/IF) over subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I-II Hodgkin’s disease: the EORTC-GPMC H7F randomized trial. Proc Am Soc Clin Oncol 16: Abstr 44

    Google Scholar 

  • Diehl V (2003) Deutsche Hodgkin Lymphom Studiengruppe. HD13-HD15 Studienprotokolle der Primärtherapie, Köln

    Google Scholar 

  • Diehl V, Franklin J, Pfreundschuh M (2003) Standard and increaseddose BEACOPP chemotherapy compared with COPP ABVD for advanced Hodgkin’s disease. N Engl J Med 348(24): 2386–2395

    Article  CAS  PubMed  Google Scholar 

  • Engert A, Schiller P, Jostin A et al. (2003) Involved-field radiotherapy is equaly effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21(19): 3601–3608

    Article  PubMed  Google Scholar 

  • Jaffe ES, Harris NL, Diebold J, Muller Hermelink HK (1999) World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 111:8

    Google Scholar 

  • Josting A, Diehl V, Engert A (2000) Behandlung und Prognose primär progredienter und rezidivierter Hodgkin-Lymphome. Onkologe 6(12):1178–1188

    Article  Google Scholar 

  • Küppers R, Re D, Wolf J, Diehl V (2000) Zellbiologie des Morbus Hodgkin. Onkologe 6(12): 1134–1141

    Google Scholar 

  • Rehwald U, Schulz H, Reiser M et al. (2003) Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101(2): 420–424

    Article  CAS  PubMed  Google Scholar 

  • Rüffer JU, Breuer K, Flechtner H (2000) Lebensqualität und Lebensquantität bei Morbus Hodgkin. Onkologe 6(12): 1189–1196

    Google Scholar 

  • Sieber M, Engert A, Diehl V (2000) Treatment of Hodgkin’s disease: Results and current concepts of the German Hodgkin’s Lymphoma Study Group. Ann Oncol 11(Suppl 1): 81–85

    PubMed  Google Scholar 

  • Sieber M, Franklin J, Tesch H et al. (2002) Two cycles ABVD plus extended-field radiotherapy is superior to radiotherapy alone in early-stage Hodgkin’s disease: results of the German Hodgkin’s Lymphoma Study Group trial HD7. Blood 100: A341

    Google Scholar 

  • Van Leeuwen FE, Klokman WJ, van’t Veer MB et al. (2000) Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence of young adulthood. J Clin Oncol 18(3) 487–497

    PubMed  Google Scholar 

Literatur

  • Allen I, Ross S, Borden S, Monroe M, Kupelnick B, Connelly J et al. (2001) Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin’s lymphoma. J Immunother 24(1): p58–65

    CAS  PubMed  Google Scholar 

  • Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE et al. (2000) High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18(3): 527–536

    CAS  PubMed  Google Scholar 

  • Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4): 235–242

    Article  CAS  PubMed  Google Scholar 

  • Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328(14): 1002–1006

    Article  CAS  PubMed  Google Scholar 

  • Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol 10(12): 1419–1432

    Article  CAS  PubMed  Google Scholar 

  • Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84(5): 1361–1392

    CAS  PubMed  Google Scholar 

  • Isaacson PG (1999) Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 36(2): 139–147

    CAS  PubMed  Google Scholar 

  • Marcus R, Imrie K., Belch A, Cunningham D, Flores E, Catalano J et al. (2004) CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood Epub ahead of Print

    Google Scholar 

  • Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C et al. (2004) 2-weekly or 3-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Elderly Patients with Aggressive Lymphomas. Result of the NHL-B2 trial of the DSHNHL. Blood 102: 634–641

    Google Scholar 

  • Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapysensitive non-Hodgkin’s lymphoma. N Engl J Med 333(23): 1540–1545

    Article  CAS  PubMed  Google Scholar 

Literatur

  • Giona F, Annino L, Rondelli R et al. (1997) Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: Results of the ALL R-87 protocol. Br J Haematol 97: 896

    Article  CAS  PubMed  Google Scholar 

  • Gökbuget N, Raff R, Brügge-Mann M, Flohr T, Scheuring U, Pfeifer H, Bartram CR, Kneba M, Hoelzer D (2004) Risk/MRD adapted GMALL trials in adult ALL. Ann Hematol 83[Suppl 1]: 129–131

    Google Scholar 

  • Hoelzer D, Ludwig W-D, Thiel E, Gabmann W, Löffler H, Fonatsch C et al. (1996) Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87: 495

    CAS  PubMed  Google Scholar 

  • Koller CA, Kantarjian HM, Thomas D et al. (1997) The HCVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 11:2039

    Article  CAS  PubMed  Google Scholar 

  • Larson RA (2004) The U.S. trials in adult acute lymphoblastic leukemia. Ann Hematol 83[Suppl 1]: 127–128

    Google Scholar 

  • Ludwig W-D, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W et al. (1998) Immunophenotype and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89. Blood 92: 1898–1909

    CAS  PubMed  Google Scholar 

  • Reiter A, Schrappe M, Ludwig W, Lampert F, Harbott J, Henze G et al. (1992) Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: A report of three consecutive studies of the BFM group. Blood 80: 2471

    CAS  PubMed  Google Scholar 

  • Roberts WM, Estrov Z, Ouspenskaia MV et al. (1997) Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 336: 317

    CAS  PubMed  Google Scholar 

  • Sierra J, Radich J, Hansen JA et al. (1997) Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 90: 1410

    CAS  PubMed  Google Scholar 

  • Zhang MJ, Hoelzer D, Horowitz MM et al. (1995) Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 123: 428

    CAS  PubMed  Google Scholar 

Literatur

  • Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330: 484–489

    Article  CAS  PubMed  Google Scholar 

  • Alsina M, Fonseca R, Wilson EF et al. (2004) Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103(9):3271–3277

    Article  CAS  PubMed  Google Scholar 

  • Attal M, Harousseau JL, Facon T et al., InterGroupe Francophone du Myelome (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349(26): 2495–2502

    Article  CAS  PubMed  Google Scholar 

  • Attal M, Harousseau JL, Stoppa AM et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2): 91–97

    Article  CAS  PubMed  Google Scholar 

  • Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. (2004) Treatment of multiple myeloma. Blood 103(1): 20–32

    Article  CAS  PubMed  Google Scholar 

  • Bjorkstrand B, Svensson H, Goldschmidt H et al. (2001) Alphainterferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 27(5): 511–515

    CAS  PubMed  Google Scholar 

  • Bundesärztekammer, Arzneimittelkommission der deutschen Ärzteschaft (2004) Bekanntmachung zu Thalidomid-haltigen Arzneimitteln. Dtsch Ärztebl 101(3): A–134

    Google Scholar 

  • Dimopoulos MA, Anagnostopoulos A, Weber D (2003) Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 21(23): 4444–4454

    Article  CAS  PubMed  Google Scholar 

  • Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. (2002) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. (3): CD003188

    Google Scholar 

  • Durie BG (1986) Staging and kinetics of multiple myeloma. Semin Oncol 13: 300–309

    CAS  PubMed  Google Scholar 

  • Durie BG, Kyle RA, Belch A et al. (2004) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Mye-loma Foundation. Hematol J 5(3): 285

    Article  Google Scholar 

  • Maloney DG, Molina AJ, Sahebi F et al. (2003) Allografting with nonmyelo-ablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102: 3447–3454

    Article  CAS  PubMed  Google Scholar 

  • Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B (2002) Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16(9): 1835–1837

    Article  CAS  PubMed  Google Scholar 

  • Richardson PG, Barlogie B, Berenson J et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26): 2609–2617

    Article  CAS  PubMed  Google Scholar 

  • Sirohi B, Powles R (2004) Multiple myeloma. Lancet 363(9412):875–887

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Markus Sieber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jürgen Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Volker Diehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcel Reiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dimitris Voliotis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Innere Medizin I, Klinikum der Universität Regensburg, D-93042, Regensburg

    Jürgen Schölmerich

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Heidelberg

About this chapter

Cite this chapter

Sieber, M., Wolf, J., Diehl, V., Reiser, M., Engert, A., Voliotis, D. (2005). Erkrankungen des lymphatischen Systems. In: Schölmerich, J., et al. Medizinische Therapie 2005|2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27385-9_30

Download citation

  • DOI: https://doi.org/10.1007/3-540-27385-9_30

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21226-3

  • Online ISBN: 978-3-540-27385-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation